1. Timothy R Rebbeck，Christine B Ambrosone，Peter G Shields.Molecular Epidemiology：Applications in Cancer and Other Human Diseases.Informa Healthcare，2008.

2. Chris Wild，Paolo Vineis，Seymour Garte.Molecular Epidemiology of Chronic Diseases.Wiley，2008.

3.詹思延.流行病学.第7版.北京：人民卫生出版社，2012.

4. Benowitz NL，Bernert JT，Caraballo RS，et al.Optimal serum cotinine levels for distinguishing cigarette smokers and nonsmokers within different racial/ethnic groups in the United States between 1999 and 2004.Am J Epidemiol，2009，169（2）：236-248.

5. Baan RA，Steenwinkel MJ，van den Berg PT，et al.Moleculardosimetry of DNA damage induced by polycyclic aromatic hydrocarbons；relevance for exposure monitoring and risk assessment. HumExpToxicol，1994，13（12）：880-887.

6. Kang DH，Rothman N，Poirier MC，et al.Interindividual differences in the concentration of 1-hydroxypyrene-glucuronide in urine and polycyclic aromatic hydrocarbon-DNA adducts in peripheral white blood cells after charbroiled beef consumption.Carcinogenesis，1995，16：1079-1085.

7. Strickland PT，Qian Z，Friesen MD，et al. Metabolites of 2-amino-1-methyl-6-phenylimidazo（4，5-b）pyridine （PhIP）in human urine after consumption of charbroiled or fried beef. Mutat Res—FundamMolecMechMutag 2002，506：163-173.

8. Tang D，Santella RM，Blackwood AM，et al.A molecular epidemiological case-control study of lung cancer.Cancer Epidemiol Biomarkers Prev，1995，4（4）：341-346.

9. Hu Z，Ma H，Lu D，et al.A promoter polymorphism（-77T＞C）of DNA repair gene XRCC1 is associated with risk of lung cancer in relation to tobacco smoking.Pharmacogenetics and Genomics，2005，15（7）：457-463.

10. Ma H，Xu L，Yuan J，et al.Tagging single nucleotide polymorphisms in excision repair cross-complementing group 1（ERCC1）and risk of primary lung cancer in a Chinese population.Pharmacogenetics and Genomics，2007，17（6）：417-423.

11. Hu Z，Xu L，Shao M，et al.Polymorphisms in the two helicases ERCC2/XPD and ERCC3/XPB of the transcription factor IIH complex and risk of lung cancer：a case-control analysis in a Chinese population.Cancer Epidemiol Biomarkers Prev，2006，15（7）：1336-1340.

12. Hu Z，Wang H，Shao M，et al.Genetic variants in MGMT and risk of lung cancer in Southeastern Chinese：a haplotype-based analysis.Hum Mutat，2007，28（5）：431-440.

13. Klein RJ，Zeiss C，Chew EY，et al.Complement factor H polymorphism in age-related macular degeneration.Science，2005，308（5720）：385-389.

14. Hung RJ，McKay JD，Gaborieau V，et al.A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25.Nature，2008，452（7187）：633-637.

15. Amos CI，Wu X，Broderick P，et al.Genome-wide association scan of tag SNPs identifies a susceptibility locus for lung cancer at 15q25. 1.Nat Genet，2008，40（5）：616-622.

16. Yeager M，Orr N，Hayes RB，et al.Genome-wide association study of prostate cancer identifies a second risk locus at 8q24.Nat Genet，2007，39（5）：645-649.

17. Easton DF，Pooley KA，Dunning AM，et al.Genome-wide association study identifies novel breast cancer susceptibility loci.Nature，2007，447（7148）：1087-1093.

18. Tomlinson I，Webb E，Carvajal-Carmona L，et al.A genome-wide association scan of tag SNPs identifies a susceptibility variant for colorectal cancer at 8q24.21.Nat Genet，2007，39（8）：984-988.

19. Gudmundsson J，Sulem P，Gudbjartsson DF，et al.Common variants on 9q22.33 and 14q13.3 predispose to thyroid cancer in European populations.Nat Genet，2009，41（4）：460-464.

20. Hu Z，Wu C，Shi Y，et al.A genome-wide association study identifies two new lung cancer susceptibility loci at 13q12.12 and 22q12.2 in Han Chinese.Nat Genet，2011，43（8）：792-796.

21. Hu Z，Wang L，Wei Q.Chapter 12：Molecular Epidemiology of DNA Repair and Cancer Susceptibility a Review of Population-based Studies//Wei Q，Li L，Chen D.DNA Repair，Genetic Instability，and Cancer.Singapore：World Scientific Publishing Co.Pte.Ltd.，2007：315-343.

22. Wacholder S.Practical considerations in choosing between the case-cohort and nested casecontrol designs.Epidemiology，1991，2（2）：155-158.

23. Ross RK，Yuan JM，Yu MC，et al.Urinary aflatoxin biomarkers and risk of hepatocellular carcinoma.Lancet，1992，339（8799）：943-946.

24. Gurubhagavatula S，Liu G，Park S，et al.XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy.J ClinOncol，2004，22（13）：2594-2601.

25. Liao WY，Shih JY，Chang GC，et al.Genetic polymorphism of XRCC1 Arg399Gln is associated with survival in non-small-cell lung cancer patients treated with gemcitabine/platinum.J ThoracOncol，2012，7（6）：973-981.

26. Dong J，Ren B，Hu Z，et al MDM2 SNP309 contributes to non-small cell lung cancer survival in Chinese.Mol-Carcinog，2011，50（6）：433-438.

27. Dong J，Hu Z，Shu Y，et al.Potentially functional polymorphisms in DNA repair genes and non-small-cell lung cancer survival：a pathway-based analysis.MolCarcinog，2012，51（7）：546-552.

28. Joerger M，Burgers JA，Baas P，et al.Gene polymorphisms，pharmacokinetics，and hematological toxicity in advanced non-small-cell lung cancer patients receiving cisplatin/gemcitabine.Cancer ChemotherPharmacol，2012，69（1）：25-33.

29. Tibaldi C，Giovannetti E，Vasile E，et al.Correlation of CDA，ERCC1，and XPD polymorphisms with response and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients.Clin Cancer Res，2008，14（6）：1797-1803.

30. Gu S，Wu Q，Zhao X，et al.Association of CASP3 polymorphism with hematologic toxicity in patients with advanced non-small-cell lung carcinoma treated with platinum-based chemotherapy.Cancer Sci，2012，103（8）：1451-1459.

31. Hu L，Wu C，Zhao X，et al.Genome-Wide Association Study of Prognosis in Advanced Non-Small Cell Lung Cancer Patients Receiving Platinum-Based Chemotherapy.Clin Cancer Res，2012，18（19）：5507-5514.

32. Curtis D.Use of siblings as controls in case-control association studies.Ann Hum Genet.1997，61（Pt 4）：319-333.

33. Spielman RS，Ewens WJ.A sibship test for linkage in the presence of association：the sib transmission/disequilibrium test.Am J Hum Genet，1998，62（2）：450-458.

34. KhouryMJ.Case-parental control method in the search for disease-susceptibility genes.Am J Hum Genet，1994，55（2）：414-415.

35. Yang Q，Khoury MJ，Sun F，et al.Case-only design to measure gene-gene interaction.Epidemiology，1999，10 （2）：167-170.

36. Hecht SS. Human urinary carcinogen metabolites：biomarkers for investigating tobacco and cancer. Carcinogenesis，2002，23（6）：907-922.

37. Scherag A，Müller HH，Dempfle A，et al.Data adaptive interim modification of sample sizes for candidate-gene association studies.Hum Hered，2003，56：56-62.

38. Pfeiffer RM，Gail MH.Sample size calculations for population-and family-based case-control association studies on marker genotypes.Genet Epidemiol，2003，25：136-148.

39. Hong EP，Park JW.Sample size and statistical power calculation in genetic association studies.Genomics Inform，2012，10（2）：117-122.

40. Lohmueller KE，et al，Meta-analysis of genetic association studies supports a contribution of common variants to susceptibility to common disease.Nat Genet，2003.33（2）：177-182.

41. Dong LM，Potter JD，White E，et al.Genetic susceptibility to cancer：the role of polymorphisms in candidate genes.JAMA，2008，299（20）：2423-2436.

42. Wellcome Trust Case Control Consortium.Genome-wide association study of 14，000 cases of seven common diseases and 3，000 shared controls.Nature，2007，47（7145）：661-678.

43. Wang K，Li M，Bucan M.Pathway-based approaches for analysis of genomewide association studies.Am J Hum Genet，2007，81（6）：1278-1283.

44. G Göring HH，Curran JE，Johnson MP，et al.Discovery ofexpression QTLs using large-scale transcriptional profilingin human lymphocytes.Nat Genet，2007，39（10）：1208-1216.